Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
microtubule inhibitor
|
| gptkbp:clinical_trial |
gptkb:Athenex,_Inc.
gptkb:Europe gptkb:United_States gptkb:Native_American_tribe Phase IV Phase II Phase III Phase I randomized controlled trial results pending |
| gptkbp:collaborations |
various research institutions
ongoing with universities |
| gptkbp:criteria |
under evaluation
|
| gptkbp:developed_by |
gptkb:Athenex,_Inc.
|
| gptkbp:dosage_form |
varies by cancer type
|
| gptkbp:effective_date |
not yet approved
|
| gptkbp:formulation |
ongoing
oral |
| https://www.w3.org/2000/01/rdf-schema#label |
Athenex's oral paclitaxel
|
| gptkbp:ingredients |
gptkb:paclitaxel
|
| gptkbp:invention |
patented
|
| gptkbp:investment |
high
|
| gptkbp:is_used_for |
treatment of cancer
|
| gptkbp:manager |
oral administration
|
| gptkbp:market |
under investigation
|
| gptkbp:objective |
reduce side effects
enhance patient compliance improve oral bioavailability increase efficacy |
| gptkbp:population |
adult patients
|
| gptkbp:products |
filed with FDA
filed with EMA under investigation for various cancers |
| gptkbp:publishes |
published in medical journals
|
| gptkbp:receives_funding_from |
secured from investors
secured from grants |
| gptkbp:regulatory_compliance |
pending
|
| gptkbp:research |
oncology research
|
| gptkbp:research_focus |
oral delivery of chemotherapy
|
| gptkbp:safety_features |
under evaluation
|
| gptkbp:side_effect |
fatigue
nausea vomiting hair loss neutropenia |
| gptkbp:student_enrollment |
ongoing
|
| gptkbp:targets |
gptkb:healthcare_organization
ovarian cancer |
| gptkbp:treatment |
may be used with other agents
|
| gptkbp:bfsParent |
gptkb:Athenex
|
| gptkbp:bfsLayer |
3
|